Cyproterone Acetate And Ethinylestradiol Tablets

Ginette-35 Contraceptive Pill (Generic Cyproterone Acetate and Ethinylestradiol Tablets) - Product Information

Ginette-35 Contraceptive Pills are used for the treatment of androgen-dependent conditions such as hirsutism, acne, and seborrhea, as well as for the management of symptoms associated with PCOS. Additionally, they are widely used as an oral contraceptive for the prevention of pregnancy.
Ginette-35 Contraceptive Tablets combine two active ingredients, Ethinyl Estradiol and Cyproterone Acetate, in a single formulation. Ethinyl Estradiol (Ethinyl Oestradiol) is a synthetic estrogen, while cyproterone acetate is an antiandrogen. This combination medication is primarily used in the treatment of conditions related to androgen excess and as an oral contraceptive. It should not be used in women solely for contraception, but should be reserved for those women requiring treatment for the androgen-dependent conditions described.
Ginette-35 tablets are manufactured by Cipla Limited, India in the strengths of 2 mg Cyproterone Acetate, and 0.035 mg Ethinylestradiol. We also have in stock Generic Alesse (Ovral-L Contraceptive Tablets by Wyeth) which is a low dose combination of Ethinyl Estradiol and Levonorgestrel used to prevent pregnancy.

Name of the Drug

We supply original Ginette-35 Contraceptive Tablets manufactured by Cipla Limited, India.

Manufacturer of Ginette-35 Contraceptive Tablets

Cipla Ltd. 
Website: www.cipla.com

Active Ingredient present in Ginette-35 Contraceptive Tablets

The active ingredients present in Ginette-35 Contraceptive tablets are Cyproterone Acetate, and Ethinyl Estradiol (Ethinylestradiol or Ethinyl Oestradiol). Each film-coated Ginette-35 tablet contains: 2 mg of Cyproterone Acetate and 0.035 mg (35 micrograms) of Ethinylestradiol (Ethinyl Oestradiol).

Uses of Ginette-35 Contraceptive Tablets (Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets)

Ginette-35 Contraceptive tablets are used for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. Ginette 35 will also provide effective oral contraception in this patient group. For the treatment of acne, Ginette 35 should only be used after topical therapy or systemic antibiotic treatments have failed. Since Ginette 35 is also a hormonal contraceptive, it should not be used in combination with other hormonal contraceptives.

Mechanism of Action

Cyproterone Acetate is a competitive antagonist on the androgen receptor, has inhibitory effects on the androgen-synthesis in target cells and produces a decrease on the androgen blood concentration through an anti-gonadotropic effect.
This anti-gonadotropic effect is amplified by ethinylestradiol which also up-regulates the synthesis of Sex-Hormone-Binding Globulin (SHBG) in plasma. By this mechanism, it reduces free, biologically available androgen in the circulation.

Ginette-35 Contraceptive Tablets - Dosage

Ginette-35 inhibits ovulation and, thereby, prevents conception. Patients who are using Ginette-35 should not, therefore, use an additional hormonal contraceptive, as this will expose the patient to an excessive dose of hormones and is not necessary for effective contraception.
First Treatment course One tablet daily for 21 days following the arrows, starting on the first day of the menstrual cycle (the first day of menstruation counting as day 1).
Subsequent Courses: Each subsequent course is started after 7 tablet-free days have followed the preceding course.
When the contraceptive action of Ginette-35 is also to be employed, it is essential that the above instructions be rigidly adhered to. Should bleeding fail to occur during the tablet-free interval, the possibility of pregnancy must be excluded before the next pack is started.
Please consult your doctor for exact dosing instructions. tablets (Generic tablets) should be administered in the dose prescribed by the doctor and for the duration recommended by the doctor.

Changing From Other Oral Contraceptive to Ginette-35 Contraceptive Tablets

Changing from 21-Day Combined Oral Contraceptives (COCs)
The first tablet of Ginette 35 should be taken on the first day immediately after the end of the previous COC course. Additional contraceptive precautions are not required.
Changing from a Combined Every Day Pill (28 day tablets)
Ginette 35 should be started after taking the last hormone containing tablet from the Every Day Pill pack. The first tablet of Ginette 35 is taken the next day. Additional contraceptive precautions are not then required.
Changing from a Progestogen- only Pill (POP)
The first tablet of Ginette 35 should be taken on the first day of bleeding, even if a POP has already been taken on that day. Additional contraceptive precautions are not then required. The remaining POPs should be discarded.

Ginette-35 Contraceptive Tablets - Storage

Store Ginette-35 Contraceptive Tablets at controlled room temperature (59°F to 86°F, 15°C to 30°C). Protect from light.

Ginette-35 Contraceptive Tablets - Contraindications

Ginette-35 Contraceptive tablets are contraindicated in patients with a hypersensitivity to Cyproterone Acetate, Ethinyl Estradiol or any inactive ingredient present in tablets. Ginette-35 Contraceptive tablets are also contraindicated in the following cases. Should any of the conditions below appear for the first time during their use, the product should be stopped immediately

• Concomitant use with another hormonal contraceptive.
• Venous thrombosis present or in history (e.g. deep venous thrombosis, pulmonary embolism)
• Arterial thrombosis present or in history (e.g. myocardial infarction) or prodromal conditions (e.g. angina pectoris and transient ischaemic attack)
• Presence or history of cerebrovascular accident
• The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis such as:diabetes mellitus with vascular symptoms, severe hypertension, severe dyslipoproteinaemia
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
• History of migraine with focal neurological symptoms
• Presence or history of severe hepatic disease e.g. active viral hepatitis and severe cirrhosis, as long as liver function values have not returned to normal.
• Presence or history of liver tumours (benign or malignant)
• Current or history of breast cancer
• Known or suspected pregnancy
• Breastfeeding

Warnings and Precautions

Ginette-35 Contraceptive Pill Overview
Ginette-35 combines cyproterone acetate and ethinylestradiol, taken for 21 days monthly like combined oral contraceptives (COCs). Warnings mirror those for COCs, requiring doctors to weigh benefits against risks for each patient, especially if conditions worsen or new risks emerge—prompting consultation and possible discontinuation.
Circulatory Risks
It raises venous thromboembolism (VTE) risk 2 to 3 times over non-users (8-10 per 10,000 woman-years vs. 4.4), higher than Levonorgestrel COCs and elevated in the first year or after breaks; arterial events like MI or stroke also increase. Risk factors include obesity (BMI greater than 30), smoking, age greater than 35, family history, immobility (e.g., surgery, flights more than 4 hours duration), and conditions like PCOS or clotting disorders—multiple factors compound risk, contraindicating use if high. Epidemiological studies have associated the use of combined hormonal contraceptives with an increased risk for Arterial Thromboembolism (ATE) (e.g. MI, angina pectoris, stroke or TIA). Arterial thromboembolic events may be fatal.
VTE/ATE symptoms (leg swelling/pain, chest pain, breathlessness, stroke signs) demand urgent care.
Tumour Risks
Long-term COC use slightly elevates cervical/breast cancer risk (RR 1.24, fading post-10 years), with rare benign/malignant liver tumours; meningiomas link to high-dose cyproterone—stop Diane-35 if diagnosed.
Meningioma
The occurrence of meningiomas (single and multiple) has been reported in association with use of cyproterone acetate, especially at high doses of 25 mg and above and for prolonged time.
Other Precautions
Monitor for hypertension, hypertriglyceridemia, liver issues, diabetes, IBD, chloasma, or lactose intolerance (31-48 mg/tablet). Discontinue before major surgery or if hereditary VTE/ATE suspected; advise non-smoking and specialist referral as needed.
Medical Examination/Consultation
A complete medical history and physical examination should be taken prior to the initiation or reinstitution Ginette-35 tablets, guided by the contraindications and warnings.
Sexually Transmitted Infections including HIV infections and AIDS
Women should be advised that preparations like Ginette-35 do not protect against HIV infections (AIDS) and other sexually transmissible infections (STIs). The woman should be advised that additional barrier contraceptive measures are needed to prevent transmission of STIs.

Effects On Ability To Drive And Use Machines

No studies on the effects on the ability to drive and use machines have been performed. No effects on ability to drive and use machines have been observed in users of combined oral contraceptives.

ginette 35 contraceptive pill Side Effects

The most commonly reported adverse reactions with Ginette-35 Contraceptive Tablets (Cyproterone Acetate and Ethinylestradiol Tablets) are nausea, abdominal pain, increased weight, headache, depressed mood, altered mood, breast pain, breast tenderness. They occur in 1 % or more of users. There is an increased risk of thromboembolism for all women who use Cyproterone Acetate and Ethinylestradiol .

Overdosage

There have been no reports of serious deleterious effects from overdose.Symptoms that may occur in case of taking an overdose of Ginette-35 Contraceptive tablets are: nausea, vomiting and withdrawal bleeding. Withdrawal bleeding may even occur in girls before their menarche, if they have accidentally taken Ginette-35. There are no antidotes and further treatment should be symptomatic.

Ginette 35 (Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets) During Pregnancy

Ginette 35 (Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets) has been classified by the US FDA as Pregnancy Category X.
Cyproterone Acetate snd Ethinylestradiol Tablets are is not indicated during pregnancy. If pregnancy occurs during treatment with Ginette 35, further intake must be stopped.
Animal studies have revealed that feminisation of male foetuses may occur if cyproterone acetate is administered during the phase of embryogenesis at which differentiation of the external genitalia occurs.
Although the results of these tests are not necessarily relevant to man, the possibility must be considered that administration of the product to women after the 45th day of pregnancy could cause feminisation of male foetuses. It follows from this that pregnancy is an absolute contraindication for treatment with Ginette 35, and must be excluded before such treatment is started.
Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Ginette 35 Nursing Considerations

The use of Ginette 35 during lactation may lead to a reduction in the volume of milk produced and to a change in its composition. Minute amounts of the active substances are excreted with the milk. These amounts may affect the child particularly in the first 6 weeks post-partum. Mothers who are breast-feeding should be advised not to take Ginette 35 (Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets) until the nursing mother has weaned her child off breast milk.
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Ginette-35 Contraceptive Pills (Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets) Online at Only $1.15 per Pill

You can buy Generic Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets online from Clear Sky Pharmacy at a cheap price. Ginette 35 pills, manufactured by Cipla Limited, India are supplied in a blister strip of 21 tablets. The Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram tablets cost only $1.15 per unit when you place an order for 252 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith, it is without a warrant of any kind, expressed or implied.

Shipping Restriction